New Tool: ProSource
Checkout our packaging and processing solutions finder, ProSource.
Start Your Search

Oxford’s Malaria Vaccine and Booster Show Up to 80% Efficacy

The new vaccine has production in India lined up to manufacture 200 million doses next year.

Poco Bw : Adobe Stock
Poco_bw / Adobe Stock

Malaria is one of the mosquito-spread diseases that plagues developing countries. While it’s already been eradicated in most parts of the world, it still kills more than 600,000 people a year in Africa. A recent Freethink* article discussed a vaccine that aims to change that. The vaccine was developed at the University of Oxford, and when combined with a booster dose, it demonstrated up to 80% efficacy in children during a long term trial, which is significant since roughly half of malaria deaths are children under five years old.

There is currently only one approved malaria vaccine; it’s made by GSK, but it’s only 40% effective. GSK is only committed to supplying 15 million doses each year, but Africa sees about 25 million births a year, and each child needs multiple doses. Oxford reported that its vaccine is up to 77% effective at preventing clinical malaria over the course of a year, which makes it the first of its kind to hit the World Health Organization’s 75% efficacy goal. If approved, the Serum Institute of India is ready to manufacture 200 million doses a year starting in 2023.

Discover Our Content Hub
Access Healthcare Packaging's free educational content library!
Unlock Learning Here
Discover Our Content Hub
Test Your Supply Chain Smarts
Take Healthcare Packaging's supply chain quiz to prove your knowledge!
Take Quiz
Test Your Supply Chain Smarts